All News

The combination of cetuximab and encorafenib resulted in a median overall survival of 8.4 months, compared to 5.4 months in the control arm among patients with colorectal cancer.

Significant reductions in mean monthly migraine days compared with placebo were seen as early as weeks 1 through 4 in the clinical trial program for atogepant.

Although specialty pharmacies may be able to offer some of the services that a hub provider does, a hub can standardize patient and provider support across the network.

Study shows that shedding pounds potentially decreases the risk of diabetes, dyslipidemia, and high blood pressure.

Amisulpride is a selective dopamine-2 and -3 receptor antagonist that inhibits postoperative nausea and vomiting.

There are several types of bipolar disorders, including mania or hypomania and depression.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses the areas that may need further investigation to progress advanced cutaneous T cell lymphoma treatments in the future.

The medication has met the criteria of overall survival for individuals with this type of liver cancer who were previously treated with sorafenib, Merck says.

Patients with senile dementia who have silent epileptic activity show improvement when taking this medication.

Cemiplimab-rwlc is being developed by Regeneron and Sanofi under a global collaboration agreement.

Durvalumab in combination with oleclumab reduced the risk of non-small cell lung cancer disease progression or death by 56%, whereas patients receiving durvalumab and monalizumab had a 35% reduction.

The results were compared to those in the previous Pfizer-BioNTech study in people between 16 and 25 years of age who were immunized with 30 μg doses.

The combination maintained superior OS and response benefits versus sunitinib in both patients with intermediate- and poor-risk prognostic factors, the primary endpoint population, and across all randomized patients.

How would you respond to these situations?

Vascepa is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients.

Hans Eriksson, MD, PhD, the chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine.

Study results presented at an American Heart Association conference show that 34% of individuals have high blood pressure.

Education is key to providing information about proper techniques and bolstering patient safety.

Approximately 5.8 million people in the United States 65 years of age and older live with Alzheimer disease.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what research is underway in the advanced cutaneous T cell lymphoma field that she is currently keeping an eye on.

By deactivating a component of the MAPK signaling pathway, researchers were able to reduce the proportion of leukemia cells in blood and bone marrow.

Monthly treatment with evolocumab reduced LDL-C by a mean of 38% from baseline compared to placebo among patients ages 10 to 17 with heterozygous familial hypercholesterolemia.

Investigators at Stanford Medicine find that 72% of individuals who took the highest dose of ON-SXB were considered much or very much improved.

Policy makers should consider structural incentives to improve generic drug access, investigators say.

A new study examined 3 different cases of chronic urticaria being treated with cyclosporine and patients who developed reactivation of recurrent herpes zoster (HZ) following COVID-19 vaccination.

Shawn Singh, CEO of VistaGen, discusses how to improve and more effectively treat mental health disorders for returning veterans, who currently account for 20% of all suicides in the United States.

Treatment of round pneumonia should be followed up with a 2-view chest X-ray weeks later.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), discusses the SHC’s recently released Flu DRIVE Toolkit, which was designed to help overburdened health systems improve flu vaccination rates among vulnerable populations.